Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C19H35N · C4H4O4
CAS Number:
Molecular Weight:
393.56
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
229-775-5
MDL number:
Product Name
Perhexiline maleate salt, ≥98% (HPLC)
InChI key
JDZOTSLZMQDFLG-BTJKTKAUSA-N
InChI
1S/C19H35N.C4H4O4/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18;5-3(6)1-2-4(7)8/h16-20H,1-15H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
SMILES string
OC(=O)\C=C/C(O)=O.C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO: ≥5 mg/mL
storage temp.
2-8°C
Quality Level
Gene Information
human ... CPT1B(1375), CPT2(1376), MTOR(2475)
Related Categories
General description
Perhexiline maleate regulates coronary vasodilatation and blocks exercise-induced tachycardia. It is used to treat angina pectoris and variant angina. Perhexiline maleate functions as a cardiac metabolic agent. It is associated with peripheral neuropathy, high intracranial pressure with papilledema and proximal myopathy.
Application
Perhexiline maleate salt has been used as a stock for worm lifespan assay. It has also been used to block fatty acid oxidation.
Perhexiline maleate salt has been used to block fatty acid oxidation. It has also been used as 5′ adenosine monophosphate-activated protein kinase (AMPK) activator and in worm lifespan assay.
Biochem/physiol Actions
Anti-anginal metabolic modulator; carnitine palmitoyltransferase inhibitor
Perhexiline maleate is an anti-anginal metabolic modulator. It inhibits the mitochondrial enzyme carnitine palmitoyltransferase CPT-1 and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also recently found to inhibit the activity of mTORC1.
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Harel Gilutz et al.
Therapeutic drug monitoring, 34(2), 227-231 (2012-02-11)
Concomitant treatment with amiodarone and perhsexiline has been considered to be relatively contraindicated because of the hypothetical risk of potentiated adverse effects mediated by additive inhibition of carnitine palmitoyl transferase 1. To study the prevalence of adverse effects associated with
Ryuta Koishi et al.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 22(3), 343-350 (2002-05-30)
The novel colony-stimulating factor (CSF) inducer leustroducsin B (LSN-B), which was isolated from Streptomyces platensis, has been shown to have potent cytokine-inducing activities in clonal human bone marrow-derived stromal cell line KM-102 and in primary human bone marrow-derived stromal cells.
Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes
Xu C, et al.
Testing, 25(2), 523-535 (2018)
[Amphiphilic cationic drug myopathy, drug-induced lysosomal storage lipidosis].
T Kumamoto
Ryoikibetsu shokogun shirizu, (36)(36), 263-266 (2001-10-13)
Ryuichiro Yamamoto et al.
Journal of bone and mineral metabolism, 31(1), 26-33 (2012-09-27)
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification. FOP is caused by a gain-of-function mutation in ACVR1 encoding the bone morphogenetic protein type II receptor, ACVR1/ALK2. The mutant receptor causes upregulation of a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service